ClinicalTrials.gg
CompletedNCT07695792Updated Oct 22, 2026

Efficacy of Therapeutic Percutaneous Electrolysis Simple vs Multiple vs Laser Therapy in Supraspinatus Tendinopathy.

An interventional study of Simple electrolysis percutaneous and Multifiliar Electrolysis percutaneus in Tendinopathy, sponsored by Universidad Pontificia de Salamanca. Completed at 1 site in Spain. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Universidad Pontificia de Salamanca · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 5 months after the study started (first participant enrolled Jan 2026, registered Jul 2026).
Updated Oct 22, 2026Start date movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Tendinopathy with a site in Spain — 9 open to participants now, 9 under way, none of them phase 3. Tendinopathy · Spain.

Enrollment
6th of 39
90 · median 60
Started
2026
with 5 others
No phase
35 of 42
8 open now
Registered
41st of 42
by date
Lead sponsor
3 of 42
Universidad Pontificia de Salamanca

Among the 42 studies in Tendinopathy with a site in Spain, this one is the 6th largest by enrollment of the 39 interventional ones that give a count, is one of 6 that started in 2026, is one of 35 with no phase, and was the 41st registered.

Tendinopathy

399 studies on the registry are indexed under Tendinopathy; 77 are open to participants now.

Browse Tendinopathy studies →

Open to participants now

9 of the 42 studies in Tendinopathy with a site in Spain are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 46 Tendinopathy studies recruiting now, 17 (37%) set no upper age limit and 22 (48%) stop at 75 or younger; 1 takes children under 18; 7 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Tendinopathy with a site in Spain, or all of them as a file.
02

Study summary

Supraspinatus tendinopathy is one of the main pathologies that cause functional alterations in the glenohumeral joint. It reduces the quality of life of the population suffering from this injury. This pathology is the most frequent cause of pain in this joint. Symptoms are aggravated by repetitive work performed at or above shoulder height and sports that involve movements above the head.

Single-blind randomised clinical trial. The participants in this study will be patients selected from the ValleSur physiotherapy clinic in Ávila from January to May 2026. These patients will be diagnosed beforehand by an orthopaedic surgeon through a complete series of orthopaedic and complementary diagnostic tests. Following the clinical examination conducted by the principal investigator to verify the presence of tendinopathy in the supraspinatus and identify the selection criteria in the selected participants. Ultrasound imaging will be used to select the area to be treated. A single-blind clinical trial with a randomised design will be conducted, in which the evaluator will be blinded to assess the short- and medium-term efficacy of treatment with ultrasound-guided electrolysis. The results will then be compared with another intervention already performed with laser therapy for the same pathology and at the same centre.

  • Common part of the treatment: Participants included in the study receive one intervention, with four evaluations: pre-intervention, post-intervention, 24 hours and one week after the intervention.
  • Invasive procedure: The patient is placed in a prone position with their feet outside the treatment table. Before beginning the intervention, the physiotherapist uses sterile gloves and examines the area to be treated using a linear probe ultrasound scanner, 2D study, in B mode and Doppler, to identify the target tissue safely and guaranteein B-mode and Doppler mode, to identify the target tissue safely and ensure the effectiveness of the technique. Once the target area has been located, an ultrasound palpation is performed to correlate the ultrasound image with the patient's clinical condition. This image is frozen in order to measure the distance from the skin to the target tissue and select the needle, in this case 0.30 x 25 mm in length (Agupunt, Madrid, Spain). The physiotherapist then thoroughly cleans the area using sterile gauze and 2% aqueous chlorhexidine. The ultrasound probe is placed back on the target tissue, the needle inserted into the handpiece is introduced, and the contact electrode is placed in the upper area close to the needle to close the circuit. Once positioned in the area to be treated, the CE-certified electrolysis device for the percutaneous application of EPTE® galvanic current (IONCLINICS \& DEIONIC SL, Alcudia, Valencia, Spain), the intensity is programmed, which in this case is 360 µA, and the treatment time, 1 minute and 20 seconds, and the 'ON' button to start the technique, and the current begins to rise progressively until it reaches 360 µA. Once the intensity is reached, the time countdown begins (1 minute and 20 seconds).
03

Conditions studied

  • Tendinopathy

Keywords

  • electrolysis
  • Quality of life
  • pain
  • range of motion
  • laser
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Signing of both to participate in the study and to undergo invasive physiotherapy techniques.
  • Presence of symptoms (inflammation or pain) ≥ 4 weeks.
  • Positive palpation test of the supraspinatus tendon.
  • Men and women over 18 years of age.
  • Score of 3 or higher on the shoulder pain analogue scale.
  • Adequate cognitive ability for understanding.
  • Limited range of motion.
  • Rotator cuff tendinopathy confirmed by ultrasound at the study centre, either due to tendon inflammation, presence of hypoechoic areas, calcification, fibrillar disorganisation and/or neovascularisation in the supraspinatus muscle.
  • Pain in the proximal lateral part of the arm that worsens with abduction.

Exclusion criteria

Exclusion Criteria:

  • Any related acute or chronic musculoskeletal disease that may affect the results of the study.
  • Presence of neuropathic pain such as lumbar radiculopathy, which may affect the results of the study.
  • Not receiving the treatment sessions and assessments of the study.
  • History of glenohumeral fracture and rheumatoid arthritis.
  • Rheumatic, neurological or structural polymyalgia affecting the joint.
  • Pregnancy.
  • Patients with cardiovascular disease.
  • Patients with neurological disease.
  • Local infection.
  • Tumours.
  • Belonephobia.
  • Taking anticoagulants or antiplatelet agents.
  • Infiltrative and/or rehabilitative treatment in the two months prior to recruitment.
  • Treatment with another intervention during the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
90 participants (actual)

Study arms

  • Active comparator
    Simple electrolysis percutaneous

    Treatment with simple electrolysis for shoulder tendinopathy.

    Device: Simple electrolysis percutaneous

  • Active comparator
    Multifiliar Electrolysis percutaneus

    Treatment with multifilar electrolysis for shoulder tendinopathy.

    Device: Multifiliar Electrolysis percutaneus

  • Experimental
    Laser

    Laser on supraspinatus tendon.

    Device: Laser

Interventions

  • DeviceSimple electrolysis percutaneous

    Treatment with simple electrolysis for shoulder tendinopathy.

  • DeviceMultifiliar Electrolysis percutaneus

    Treatment with multifilar electrolysis for shoulder tendinopathy.

  • DeviceLaser

    laser on supraspinatus tendon.

06

What researchers measure

Primary outcomes

  1. Intensity of pain

    measured using the VAS scale, where 0 is the least possible pain and 10 is the greatest possible pain

    Time frame: 1 week

Secondary outcomes

  1. Range of motion

    Shoulder mobility in the joint ranges of flexion, extension, abduction, adduction, and external and internal rotation. Measurement in degrees using a goniometer

    Time frame: 1 week

  2. Patient quality of life

    DASH questionnaire The score ranges from 0, which is equivalent to having no disability, to a maximum of 100, which is equivalent to having a very severe functional limitation.

    Time frame: 1 week

07

Study locations

1 site
  • Universidad Pontificia de Salamanca
    Salamanca, 37002, Spain
08

References and documents

Publications

  • Sanchez-Sanchez JL, Calderon-Diez L, Herrero-Turrion J, Mendez-Sanchez R, Arias-Buria JL, Fernandez-de-Las-Penas C. Changes in Gene Expression Associated with Collagen Regeneration and Remodeling of Extracellular Matrix after Percutaneous Electrolysis on Collagenase-Induced Achilles Tendinopathy in an Experimental Animal Model: A Pilot Study. J Clin Med. 2020 Oct 15;9(10):3316. doi: 10.3390/jcm9103316. PubMed 33076550 ↗
  • Redondo-Alonso L, Chamorro-Moriana G, Jimenez-Rejano JJ, Lopez-Tarrida P, Ridao-Fernandez C. Relationship between chronic pathologies of the supraspinatus tendon and the long head of the biceps tendon: systematic review. BMC Musculoskelet Disord. 2014 Nov 18;15:377. doi: 10.1186/1471-2474-15-377. PubMed 25408141 ↗
  • Haik MN, Alburquerque-Sendin F, Moreira RF, Pires ED, Camargo PR. Effectiveness of physical therapy treatment of clearly defined subacromial pain: a systematic review of randomised controlled trials. Br J Sports Med. 2016 Sep;50(18):1124-34. doi: 10.1136/bjsports-2015-095771. Epub 2016 Jun 10. PubMed 27288517 ↗
  • Romero-Morales C, Bravo-Aguilar M, Abuin-Porras V, Almazan-Polo J, Calvo-Lobo C, Martinez-Jimenez EM, Lopez-Lopez D, Navarro-Flores E. Current advances and novel research on minimal invasive techniques for musculoskeletal disorders. Dis Mon. 2021 Oct;67(10):101210. doi: 10.1016/j.disamonth.2021.101210. Epub 2021 Jun 4. PubMed 34099238 ↗
  • Asensio-Olea L, Leiros-Rodriguez R, Marques-Sanchez MP, de Carvalho FO, Maciel LYS. Efficacy of percutaneous electrolysis for the treatment of tendinopathies: A systematic review and meta-analysis. Clin Rehabil. 2023 Jun;37(6):747-759. doi: 10.1177/02692155221144272. Epub 2022 Dec 30. PubMed 36583575 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2026 to primary completion in Jul 2026, 6 months.

Of 174 non-industry interventional studies with no phase under Tendinopathy, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 38. This study's 6 months is below that.

Counting every sponsor, half of 183 studies reached it within 20 months; a quarter within 7 and three quarters within 37.

Start moved once since we started tracking on Sep 25, 2026: Jul 2026 → Jan 2026, on Oct 22, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2026
First posted
Jul 10, 2026
StartActual
Jan 11, 2026was Jul 2026
Primary completionActual
Jul 19, 2026
CompletionActual
Aug 4, 2026
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Jul 1, 2026→Jan 11, 2026
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    Start date Jul 1, 2026→Jan 11, 2026
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07695792
Lead sponsor
Universidad Pontificia de Salamanca
Responsible party
Jorge Velazquez (Principal Investigator, Universidad Pontificia de Salamanca) — Principal investigator
First posted
Jul 10, 2026
Start date
Jan 11, 2026
Primary completion
Jul 19, 2026
Completion
Aug 4, 2026
Last update
Oct 22, 2026

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion